|
|
Latest oncology clinical development updates
Monday, February 09, 2026
|
|
|
|
|
OTW News Highlights this week
|
|
|
|
|
|
|
|
|
“Today’s FDA approval of sevabertinib as an initial treatment option for locally advanced or metastatic non-squamous HER2-mutated NSCLC is an important milestone for patients and a powerful validation of Bayer’s commitment to advancing precision oncology in areas with the highest unmet needs,” said Christine Roth, Executive Vice President, Global Product Strategy and Commercialization and Member of the Pharmaceuticals Leadership Team …
|
|
|
|
|
|
|
|
"These regulatory clearances represent an important milestone for FL-261 and our strategy to expand targeted alpha therapy into various solid tumors," said Debora Barton, MD, Chief Medical Officer of Full-Life Technologies. "Ac-FL-261 is designed to selectively target c-MET-expressing tumors by delivering potent alpha radiation directly into the tumor sites. We look forward to advancing FL-261 into its Phase 1 trial …
|
|
|
|
|
|
|
|
“This financing, together with FDA clearance of the IND, marks an important inflection point for TwoStep and positions us to advance TS-104, our lead peptide-drug conjugate, through Phase 1 clinical development in oncology. This trial will provide the first clinical evaluation of the multi-specific targeting approach at the heart of TwoStep and begin to assess its potential to broaden the …
|
|
|
|
|
|
|
|
“The Nanobiotix team is encouraged by these full-cohort findings in one of the most difficult settings in lung cancer,” said Louis Kayitalire, MD, Chief Medical Officer of Nanobiotix. “If a physics-based approach can improve local control in tissue that has already failed radiation, and do so at a reduced dose, then the conditions in earlier settings, where full-dose radiotherapy reaches …
|
|
|
|
|
|
|
|
"We are extremely excited to report initial results from SURF302 today as we work to advance what we believe could become the first once-daily oral therapy for patients with low-grade IR NMIBC," said Todd Harris, Ph.D., Chief Executive Officer of TYRA Biosciences. "These results belong first and foremost to the patients participating in SURF302 and the investigators and study teams …
|
|
|
|
|
|
|
|
"For us, this starts with the patient," said Scott Liu, Ph.D., Founder and Chairman of HanchorBio. "When a patient is benefiting from an investigational therapy and has limited treatment options, we believe every appropriate avenue to continue access should be considered. HCB101 was created to make a meaningful difference, and this milestone reflects the patient-first principle guiding our FBDB™ platform."
|
|
|
|
|
|
|
|
Immutep CEO, Marc Voigt, said: “Based on the totality of evidence generated with efti, we believe there is a scientifically and clinically justified path to continue its development. This includes clinical and translational data across multiple tumour types, consistent evidence of immune activation, encouraging results in soft tissue sarcoma and head and neck cancer with CPS < 1, and constructive …
|
|
|
|
|
|
|
|
"We are pleased to see Solstice Oncology launch with strong support from leading investors and advance porustobart into the neoadjuvant setting," said Dr. Jingsong Wang, Founder, Chairman and CEO of Harbour BioMed. "As the originator of porustobart and a partner of Solstice, we look forward to supporting the continued development of this differentiated CTLA-4 antibody and exploring its potential to …
|
|
|
|
|
|
|
|
"We are pleased with the progress of this collaboration and the first lead selection. We look forward to delivering transformational therapies to patients through this highly productive partnership," said Peter Lebowitz, M.D., Ph.D., Chief Executive Officer of Third Arc Bio.
|
|
|
|
|
|
|
|
Author
Managing Editors
Social Media Managers
|
|
|
|
|
|
Disclaimer: The OTW team takes care to share authentic information. In case of any discrepancies please write to newsletter@onco-this-week.com. Our website is an aggregator for open-source oncology news. The information on our website is provided without any representations or warranties. OTW is a part of RLS Consultants, which is a global consulting and training firm focusing exclusively on the healthcare and life sciences industries. RLS is a leading provider of opportunity assessment services, utilizing its comprehensive expertise in strategic market research, forecasting, and modeling, as well as pricing and market access to facilitate commercial assessments. RLS does not have any influence on any news reported on OTW. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of RLS. The content on our website is intended strictly for news and information purposes only and should not be treated as a substitute for medical advice, diagnosis, or treatment. News shared on OTW should not be utilized in real-world analytic products as they are based only on limited and dated open-source information.
|
|
|
|
|
|
|
